Request Demo
Last update 21 Jan 2025
Dexrazoxane Hydrochloride
Last update 21 Jan 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms dexrazoxane, Topotect, Totect + [13] |
Target |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (26 May 1995), |
RegulationAccelerated Approval (US), Orphan Drug (US), Orphan Drug (AU) |
Login to view timeline
Structure/Sequence
Molecular FormulaC11H17ClN4O4 |
InChIKeyBIFMNMPSIYHKDN-FJXQXJEOSA-N |
CAS Registry149003-01-0 |
Related
51
Clinical Trials associated with Dexrazoxane HydrochlorideNCT06647953
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
NCT06220032
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial
NCT06262438
A Phase II, Single Arm, Open Label, Study on the Safety, Efficacy, Pharmacokinetics & Pharmacodynamics of Quizartinib + Chemotherapy and as Single-agent After High Dose Therapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
100 Clinical Results associated with Dexrazoxane Hydrochloride
Login to view more data
100 Translational Medicine associated with Dexrazoxane Hydrochloride
Login to view more data
100 Patents (Medical) associated with Dexrazoxane Hydrochloride
Login to view more data
868
Literatures (Medical) associated with Dexrazoxane Hydrochloride01 Feb 2025CARDIOLOGY CLINICS
Cardiotoxicity of Anthracyclines
Review
Author: Hoeger, Christopher W. ; Ariza, Abul ; Balough, Elizabeth ; Asnani, Aarti ; Hoeger, Christopher W
Anthracycline chemotherapy is associated with cardiotoxicity, predominantly manifesting as left ventricular systolic dysfunction within the first year of treatment. Early detection is possible through biomarkers and cardiovascular imaging before clinical symptoms develop. Comprehensive cardiovascular risk assessment is essential for all patients prior to anthracycline therapy to stratify their risk of cardiotoxicity. Preventive measures, including cardiovascular risk optimization, as well as anthracycline dose adjustments, the use of liposomal anthracyclines, and dexrazoxane in high-risk patients, are crucial to mitigate the risk of cardiotoxicity. Long-term follow-up and cardiovascular risk optimization are critical for cancer survivors to optimize cardiovascular outcomes.
01 Jan 2025JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Hepatoblastoma in a 13-Month-old Male With Oculofaciocardiodental Syndrome
Article
Author: Masse, Diana ; Seelisch, Jennifer ; Prasad, Chitra ; Kumar, Kriti
Background::
Oculofaciocardiodental (OFCD) syndrome is an X-linked dominant condition that is typically lethal in males.
Observations::
A 13-month-old male patient with OFCD syndrome presented with hepatoblastoma. He received chemotherapy per standard of care and had a surgical resection with few complications. He received sodium thiosulfate for otoprotection and dexrazoxane for cardioprotection. Five years after diagnosis, he remains well and in remission.
Conclusions::
Malignancies have been reported in patients with OFCD syndrome; however, our patient is the only male with OFCD syndrome described with hepatoblastoma. Given the rarity of this condition, malignancy may be part of the spectrum of disease.
01 Jan 2025Journal of Natural Medicines
Preventive effect of imperatorin against doxorubicin-induced cardiotoxicity through suppression of NLRP3 inflammasome activation
Article
Author: Bao, Huiyun ; Wang, Hu ; Zhang, Hao ; Xie, Mengdie ; Tang, Xilan ; Xiong, Yinhua ; Huang, Si ; Li, Tingting ; Qiu, Yumei ; Ding, Xiaoyun
Cardiotoxicity is one of the major obstacles to anthracycline chemotherapy. Anthracycline cardiotoxicity is closely associated with inflammation. Imperatorin (IMP), a furocoumarin ingredient extracted from Angelica dahurica, might have potential activity in preventing anthracycline cardiotoxicity due to its anti-cancer, anti-inflammatory, anti-oxidant, cardioprotective properties. This study aims to reveal the effect of IMP on doxorubicin (DOX)-induced cardiotoxicity and its underlying mechanism. We established a rat model of DOX-induced cardiotoxicity by intraperitoneal injection with DOX (1.25 mg/kg twice weekly for 6 weeks), and found that both IMP (25 mg/kg and 12.5 mg/kg) and dexrazoxane 12.5 mg/kg relieved DOX-induced reductions in heart weight, change in cardiac histopathology, and elevated serum levels of LDH, AST and CK-MB. Moreover, DOX upregulated mRNA levels of NLRP3, CASP1, GSDMD, ASC, IL-1β and IL-18, elevated protein expressions of NLRP3, ASC, GSDMD-FL, GSDMD-N, pro‑caspase‑1, caspase‑1 p20, pro‑IL‑1β and IL‑1β in heart tissues, as well as increased serum levels of pro-inflammatory cytokines including IL-1β and IL-18, however both of IMP and dexrazoxane suppressed these alterations. In addition, we carried out neonatal rat cardiomyocytes experiments to confirm the results of the in vivo study. Consistently, pretreatment with IMP 25 µg/mL relieved DOX (1 μg/mL)-induced cardiomyocytes injury, including decreased cell viability and reduced supernatant LDH. IMP inhibited DOX-induced activation of NLRP3 inflammasome in cardiomyocytes. In conclusion, IMP had a protective effect against DOX-induced cardiotoxicity via repressing the activation of NLRP3 inflammasome. These findings suggest that IMP may be a promising alternative or adjunctive drug for the prevention of anthracycline cardiotoxicity.
3
News (Medical) associated with Dexrazoxane Hydrochloride11 Aug 2023
AcquisitionLicense out/in
10 Aug 2023
AcquisitionRadiation Therapy
09 Feb 2019
Accelerated ApprovalOrphan DrugFast TrackBreakthrough TherapyDrug Approval
100 Deals associated with Dexrazoxane Hydrochloride
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D07807 | Dexrazoxane Hydrochloride |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Extravasation of Diagnostic and Therapeutic Materials | EU | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | IS | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | LI | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | NO | 27 Jul 2006 | |
| Cytoprotective Agent | CN | 29 May 2006 | |
| Cardiomyopathies | US | 26 May 1995 | |
| Metastatic breast cancer | US | 26 May 1995 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hemorrhage | Phase 3 | DK | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | DE | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | IT | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | NL | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | PL | 01 Apr 2002 | |
| Bronchitis | Phase 3 | DK | 01 Jun 2001 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | cenxlkzquw(tavibcozsd) = clhkytxuha ceizlsprim (matpvddzny ) View more | - | 07 Dec 2024 | |||
Non-initiators of Dexrazoxane | cenxlkzquw(tavibcozsd) = cbtzucwioz ceizlsprim (matpvddzny ) View more | ||||||
Not Applicable | 142 | Anthracycline + Dexrazoxane | zjwklwxmlr(resbtikzjo) = wixxrwobkx wioqpenxeh (zruxspnwmf ) | Positive | 31 May 2023 | ||
Anthracycline only | zjwklwxmlr(resbtikzjo) = goajhjrxae wioqpenxeh (zruxspnwmf ) View more | ||||||
Not Applicable | 263 | pyecajeyls(acjucawlvh) = vmpzfzsarp xqxzewfnnn (hugguvuiuq ) View more | - | 03 Dec 2022 | |||
pyecajeyls(acjucawlvh) = kmpthyximp xqxzewfnnn (hugguvuiuq ) View more | |||||||
Not Applicable | - | 1,308 | Doxorubicin with dexrazoxane | pvvadhzhax(uzrkyelrcy): HR = 1.07 (95% CI, 0.78 - 1.47) View more | - | 15 Feb 2022 | |
Doxorubicin without dexrazoxane | |||||||
Phase 3 | 236 | Therapeutic Conventional Surgery (Very Low-risk Group) | cbzwbrfrin(frrdrqeyst) = srgnaoehhc voigzcmioe (kerxvoejtz, vqrarwnsjx - ewhnugzudh) View more | - | 28 Dec 2021 | ||
(Low-risk Group (Regimen T)) | cbzwbrfrin(frrdrqeyst) = cfvtevoqgx voigzcmioe (kerxvoejtz, ghsomgdwwr - ojjbteypdo) View more | ||||||
Not Applicable | 2,375 | slafovpxlf(cvrxhzkwhn): OR = 1.15 (95% CI, 0.57 - 2.31), P-Value = 0.7 View more | - | 29 Jun 2021 | |||
No drug or placebo | |||||||
Not Applicable | 173 | agqjbefjly(dnuypzsymh) = wxypxlfdvr xiyphwaxda (aexfiubcvu, 6.0 - 18.0) View more | Positive | 25 May 2020 | |||
agqjbefjly(dnuypzsymh) = slwycnemfk xiyphwaxda (aexfiubcvu, 6.0 - 28.2) View more | |||||||
Phase 2 | 46 | (Arm A: VACdxr With ImmTher) | iznwvexrox(egrbsmqbwr) = rdiiiuidel tvdezxterk (yrsfjgilcv, uvxpfuajzv - uplccphkfk) View more | - | 29 Jan 2020 | ||
(Arm B: VACdxr) | iznwvexrox(egrbsmqbwr) = sgyamgqbkb tvdezxterk (yrsfjgilcv, hiehlkynwz - uxesyqufyt) View more | ||||||
Phase 1 | 1 | wbvypdghwt(cjpopcbwse) = occpozdkgn ckqosereax (vehvilyyvk, iaohkcbkab - wsdqxtonzd) View more | - | 19 Feb 2019 | |||
Not Applicable | Breast Cancer Adjuvant | 1,545 | kmsouxwcli(faeaywyssc): RR = 0.262 (95% CI, 0.169 - 0.407) View more | Positive | 01 Jun 2018 | ||
Anthracycline-based chemotherapy |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free